Growing Pipeline of ADC Candidates for Various Cancer Indications is Driving the IndustryDublin, April 25, 2025 (GLOBE NEWSWIRE) -- The "Antibody Drug Conjugates Market - Global Industry Size, Share, ...

CatalYm today announced the presentation of the first preclinical data demonstrating that the company’s clinical-stage ...

Lotte Biologics, the biotech arm of Lotte Group, said on Thursday it has signed a deal with an Asia-based biotech company for ...

Antibody-drug conjugates combined with immunotherapy have redefined the standard of care for advanced bladder cancer, ...

Duchenne muscular dystrophy (DMD) is a devastating genetic disorder affecting approximately 1 in 3,500-5,000 newborn males worldwide. It is characterized by progressive degeneration of skeletal, ...

Antibody drug conjugates (ADCs) represent a revolutionary class of therapeutics, blending precision targeting with potent ...

Anti-IL1RAP ADC demonstrated potent anti-tumor efficacy and was well tolerated in pre-clinical modelsAnti-IL1RAP ADC targets IL1RAP, which is overexpressed in many tumors and their tumor microenvironm ...

In this interview, Technology Networks spoke with Dr. Lena Jonsson, product strategy manager at Cytiva, to explore the biological, clinical and technological frontiers shaping the next generation of ...

The theory behind antibody drug conjugates (ADCs) is simple yet elegant: by combining the specificity of a monoclonal antibody with the cytotoxicity of a potent small molecule drug, ADCs can ...

Vantage Market Research report examines the Antibody Drug Conjugates (ADCs) market, forecasting trends and dynamics from 2025 to 2035. The report highlights the significance of ADCs in modern oncology ...